eMedicine Specialties > Emergency Medicine > Cardiovascular
Wolff-Parkinson-White Syndrome: Follow-up
Updated: Aug 19, 2008
Follow-up
Further Inpatient Care
- Arrange consultation with a cardiologist for patients admitted with Wolff-Parkinson-White (WPW) syndrome because these patients are at high risk of sudden death if they develop AFib. Those who can be treated and discharged should also have urgent cardiology follow-up. One should consider radiofrequency ablation of the accessory pathway in all patients.
Further Outpatient Care
- Follow-up with a cardiologist and cardiac electrophysiologist is recommended in the patient with any worrisome features (eg, syncope, significant symptomatic tachyarrhythmias, uncertain diagnosis in those with wide-complex tachycardia, associated structural heart disease, WPW syndrome with a family history of sudden death, recurrent atrial fibrillation or flutter).
Inpatient & Outpatient Medications
- Ongoing therapy of patients with WPW syndrome is generally interventional (radiofrequency ablation). Those patients whom receive ongoing pharmacologic therapy should do so only under the supervision of an experienced cardiologist.
Transfer
- In patients whom have experienced worrisome features (eg, syncope, significant symptomatic tachyarrhythmias, uncertain diagnosis in those with wide-complex tachycardia, associated structural heart disease, WPW syndrome with a family history of sudden death, recurrent atrial fibrillation or flutter) whom cannot achieve an urgent cardiologist and/or cardiac electrophysiologist consultation, transfer should be considered to expedite this process.
Prognosis
- Patients with WPW syndrome have an excellent prognosis when treated with radiofrequency ablation of the accessory pathway.
Patient Education
- Education is the most important aspect of outpatient care for patients with WPW. Urge patients to carry a sample ECG in sinus rhythm and a medical identification bracelet in case of cardiac arrest.
Miscellaneous
Medicolegal Pitfalls
- Failure to recognize this dysrhythmia and treatment with agents leading to deterioration (eg, beta-blockers, calcium channel blockers, digoxin) may lead to clinical deterioration and medicolegal vulnerability.
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Griffith Tully, MD, to the development and writing of this article.
More on Wolff-Parkinson-White Syndrome |
| Overview: Wolff-Parkinson-White Syndrome |
| Differential Diagnoses & Workup: Wolff-Parkinson-White Syndrome |
| Treatment & Medication: Wolff-Parkinson-White Syndrome |
Follow-up: Wolff-Parkinson-White Syndrome |
| References |
| « Previous Page |
References
Durrer D, Schuilenburg RM, Wellens HJ. Pre-excitation revisited. Am J Cardiol. Jun 1970;25(6):690-7. [Medline].
Fengler BT, Brady WJ, Plautz CU. Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the ED. Am J Emerg Med. Jun 2007;25(5):576-83. [Medline].
American Heart Association. Advanced Cardiac Life Support. 2005.
Conover MB. Diagnosis and management of arrhythmias associated with Wolff-Parkinson-White syndrome. Crit Care Nurse. Jun 1994;14(3):30-9; quiz 40-1. [Medline].
Delacretaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med. Mar 9 2006;354(10):1039-51. [Medline].
ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. Dec 13 2005;112(24 Suppl):IV1-203. [Medline].
Gaita F, Giustetto C, Riccardi R, et al. Wolff-Parkinson-White syndrome. Identification and management. Drugs. Feb 1992;43(2):185-200. [Medline].
Garratt C, Antoniou A, Ward D, et al. Misuse of verapamil in pre-excited atrial fibrillation. Lancet. Feb 18 1989;1(8634):367-9. [Medline].
Garratt CJ, Griffith MJ, O'Nunain S, Ward DE, Camm AJ. Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections. Circulation. Nov 1991;84(5):1962-8. [Medline].
Herbert ME, Votey SR. Adenosine in wide-complex tachycardia. Ann Emerg Med. Jan 1997;29(1):172-4. [Medline].
Kinsara AJ. 2000 Guidelines for Cardiopulmonary Resuscitation Emergency Cardiovascular Care. Circulation. Aug 28 2001;104(9):E45. [Medline].
Shah CP, Gupta AK, Thakur RK, et al. Adenosine-induced ventricular fibrillation. Indian Heart J. Mar-Apr 2001;53(2):208-10. [Medline].
Sharma AD, Klein GJ, Yee R. Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am J Med. Apr 1990;88(4):337-43. [Medline].
Stahmer SA, Cowan R. Tachydysrhythmias. Emerg Med Clin North Am. Feb 2006;24(1):11-40, v-vi. [Medline].
Tintinalli JE. Emergency Medicine: A Comprehensive Study Guide. McGraw-Hill; 2004.
Wellens HJ, Brugada P, Penn OC. The management of preexcitation syndromes. JAMA. May 1 1987;257(17):2325-33. [Medline].
Further Reading
Keywords
Wolff-Parkinson-White syndrome, preexcitation syndrome, atrioventricular reentrant tachycardia, AVRT, AVNRT, atrioventricular nodal reentrant tachycardia, AV nodal reentrant tachycardia, WPW syndrome, paroxysmal supraventricular tachycardia, PSVT, supraventricular tachycardia, SVT, heart disease
Follow-up: Wolff-Parkinson-White Syndrome